FI56772C - Foerfarande foer framstaellning av en beredning foer behandling av onormala tarmtillstaond - Google Patents
Foerfarande foer framstaellning av en beredning foer behandling av onormala tarmtillstaond Download PDFInfo
- Publication number
- FI56772C FI56772C FI760948A FI760948A FI56772C FI 56772 C FI56772 C FI 56772C FI 760948 A FI760948 A FI 760948A FI 760948 A FI760948 A FI 760948A FI 56772 C FI56772 C FI 56772C
- Authority
- FI
- Finland
- Prior art keywords
- preparation
- colon
- foer
- tarmtillstaond
- onormala
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 description 39
- 210000001072 colon Anatomy 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- 239000008187 granular material Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000000034 method Methods 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 229920002125 Sokalan® Polymers 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 235000015099 wheat brans Nutrition 0.000 description 6
- 206010003011 Appendicitis Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 229920000084 Gum arabic Polymers 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000010489 acacia gum Nutrition 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000010903 husk Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 229940042003 metamucil Drugs 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000001148 spastic effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241001528248 Frangula Species 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 244000134552 Plantago ovata Species 0.000 description 2
- 235000003421 Plantago ovata Nutrition 0.000 description 2
- 244000090599 Plantago psyllium Species 0.000 description 2
- 235000010451 Plantago psyllium Nutrition 0.000 description 2
- 229920000148 Polycarbophil calcium Polymers 0.000 description 2
- 239000009223 Psyllium Substances 0.000 description 2
- 235000021282 Sterculia Nutrition 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 229940124575 antispasmodic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- 229940095498 calcium polycarbophil Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- SJDACOMXKWHBOW-UHFFFAOYSA-N oxyphenisatine Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2NC1=O SJDACOMXKWHBOW-UHFFFAOYSA-N 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002689 polyvinyl acetate Polymers 0.000 description 2
- 239000011118 polyvinyl acetate Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 229940070687 psyllium Drugs 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940059107 sterculia Drugs 0.000 description 2
- 230000002522 swelling effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010013554 Diverticulum Diseases 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- RYXPMWYHEBGTRV-UHFFFAOYSA-N Omeprazole sodium Chemical compound [Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 240000001058 Sterculia urens Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7504049A SE7504049L (sv) | 1975-04-09 | 1975-04-09 | Colonpreparation |
| SE7504049 | 1975-04-09 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI760948A7 FI760948A7 (en, 2012) | 1976-10-10 |
| FI56772B FI56772B (fi) | 1979-12-31 |
| FI56772C true FI56772C (fi) | 1980-04-10 |
Family
ID=20324216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI760948A FI56772C (fi) | 1975-04-09 | 1976-04-07 | Foerfarande foer framstaellning av en beredning foer behandling av onormala tarmtillstaond |
Country Status (12)
| Country | Link |
|---|---|
| BE (1) | BE840552A (en, 2012) |
| DE (1) | DE2614296A1 (en, 2012) |
| DK (1) | DK153376A (en, 2012) |
| FI (1) | FI56772C (en, 2012) |
| FR (1) | FR2306710A1 (en, 2012) |
| GB (1) | GB1538123A (en, 2012) |
| IE (1) | IE42793B1 (en, 2012) |
| LU (1) | LU74732A1 (en, 2012) |
| NL (1) | NL7603600A (en, 2012) |
| NO (1) | NO761101L (en, 2012) |
| NZ (1) | NZ180552A (en, 2012) |
| SE (1) | SE7504049L (en, 2012) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52139715A (en) * | 1976-05-14 | 1977-11-21 | Nippon Kayaku Co Ltd | Coated granules of alkali polyacrylate |
| FR2471186A1 (fr) * | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| US4444761A (en) * | 1981-05-04 | 1984-04-24 | Syntex (U.S.A.) Inc. | Cellulose/carboxymethyl cellulose mixtures useful for controlling fecal output, and methods employing them |
| US4521401A (en) * | 1983-01-03 | 1985-06-04 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulations of quinidine |
| US4461759A (en) * | 1983-01-03 | 1984-07-24 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulations of veropamil |
| US4522804A (en) * | 1983-01-03 | 1985-06-11 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulations of propranolol |
| DE3776116D1 (de) * | 1986-12-30 | 1992-02-27 | American Cyanamid Co | Zusammensetzung die ein polycarbophil enthaelt. |
| GB8817015D0 (en) * | 1988-07-16 | 1988-08-17 | Reckitt & Colmann Prod Ltd | Method of treatment |
| BE1002406A5 (fr) * | 1988-09-20 | 1991-01-29 | Glaxo Group Ltd | Compositions pharmaceutiques. |
| IL98087A (en) * | 1990-05-04 | 1996-11-14 | Perio Prod Ltd | Preparation for dispensing drugs in the colon |
| HU210497B (en) * | 1990-05-04 | 1995-04-28 | Perio Prod Ltd | Process for production of modified pectin |
| DE9212938U1 (de) * | 1992-09-25 | 1992-11-26 | Boehringer Ingelheim Gmbh, 6507 Ingelheim | Calciumpolycarbophil-Zubereitung zur Einnahme hoher Wirkstoffdosen |
| US5840332A (en) * | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
| US10695363B2 (en) | 2017-04-14 | 2020-06-30 | Gelesis Llc | Compositions and methods for treating or preventing gut permeability-related disorders |
-
1975
- 1975-04-09 SE SE7504049A patent/SE7504049L/xx unknown
-
1976
- 1976-03-30 NO NO761101A patent/NO761101L/no unknown
- 1976-03-31 DK DK153376A patent/DK153376A/da not_active IP Right Cessation
- 1976-04-02 DE DE19762614296 patent/DE2614296A1/de not_active Withdrawn
- 1976-04-06 NL NL7603600A patent/NL7603600A/xx not_active Application Discontinuation
- 1976-04-07 FI FI760948A patent/FI56772C/fi not_active IP Right Cessation
- 1976-04-08 NZ NZ180552A patent/NZ180552A/xx unknown
- 1976-04-08 FR FR7610342A patent/FR2306710A1/fr active Granted
- 1976-04-08 GB GB14390/76A patent/GB1538123A/en not_active Expired
- 1976-04-09 IE IE749/76A patent/IE42793B1/en unknown
- 1976-04-09 LU LU74732A patent/LU74732A1/xx unknown
- 1976-04-09 BE BE165981A patent/BE840552A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK153376A (da) | 1976-10-10 |
| NO761101L (en, 2012) | 1976-10-12 |
| SE7504049L (sv) | 1976-10-10 |
| IE42793B1 (en) | 1980-10-22 |
| FI760948A7 (en, 2012) | 1976-10-10 |
| BE840552A (fr) | 1976-10-11 |
| DE2614296A1 (de) | 1976-10-21 |
| FR2306710B1 (en, 2012) | 1979-07-13 |
| IE42793L (en) | 1976-10-09 |
| NL7603600A (nl) | 1976-10-12 |
| GB1538123A (en) | 1979-01-10 |
| NZ180552A (en) | 1978-07-28 |
| LU74732A1 (en, 2012) | 1977-02-04 |
| FI56772B (fi) | 1979-12-31 |
| FR2306710A1 (fr) | 1976-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI56772C (fi) | Foerfarande foer framstaellning av en beredning foer behandling av onormala tarmtillstaond | |
| US4511561A (en) | Laxative composition comprising psyllium seeds and senna fruits | |
| Andrews et al. | Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret | |
| US11213559B2 (en) | Formulation for treatment of irritable bowel disease | |
| WO2021104155A1 (zh) | 一种解酒护肝水凝胶片及其制备方法和应用 | |
| CN101642252B (zh) | 一种苦荞颗粒的保健食品 | |
| EP0495105A1 (en) | Inhibitor of absorption of digestion product of food and drink | |
| FI75095B (fi) | Foerfarande foer framstaellning avfoeringsmedel baserat pao ratamonfroen och sennafrukter. | |
| CN101491493A (zh) | 阿魏酸哌嗪缓释药物制剂 | |
| CN100381136C (zh) | 一种治疗便秘的药物组合物及其制剂和制备方法 | |
| CN104622971A (zh) | 一种抗糖尿病活性的药物组合物及其制备方法 | |
| CN107137371A (zh) | 一种治疗口腔溃疡的双层粘贴片 | |
| RU2559590C2 (ru) | Применение полисахаридов для лечения стресса и тревоги | |
| CN106063788B (zh) | 连翘苷、连翘苷衍生物、连翘苷与连翘脂素组合物在制备缓解或/和治疗呕吐药物中的应用 | |
| CN1895520A (zh) | 一种胃铋镁颗粒及其制备方法 | |
| CN102716128A (zh) | 一种治疗哮喘的药用组合物 | |
| US2990327A (en) | Composition and method for treating biliary dyskinesia | |
| CN105687163A (zh) | 一种米拉贝隆缓释微丸及其制备方法 | |
| CN117481345B (zh) | 一种具有肠胃调节功能的壳寡糖组合物及功能糖 | |
| CN107137491A (zh) | 一种治疗甲状腺肿大的药物组合物及其制备方法 | |
| CN116813814A (zh) | 红花膳食纤维、提取方法及其在制备治疗功能性便秘药物方面的应用 | |
| CN103463290A (zh) | 一种防治胃溃疡的口服原位凝胶剂 | |
| CN103565748B (zh) | 一种聚乙二醇4000散剂 | |
| WO2006072239A2 (de) | Verwendung von cobalaminen zur behandlung von darmerkrankungen | |
| CN116473227A (zh) | 一种具有通便作用的益生元软胶囊及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: AB HAESSLE |